183 related articles for article (PubMed ID: 32825972)
1. Postoperative radiotherapy for laryngeal cancer. The prognostic role of programmed death-ligand 1: An immune microenvironment-based cluster analysis.
Franz L; Alessandrini L; Ottaviano G; di Carlo R; Fasanaro E; Ramacciotti G; Contro G; Marioni G
Pathol Res Pract; 2020 Sep; 216(9):153120. PubMed ID: 32825972
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma.
Alessandrini L; Franz L; Ottaviano G; Ghi MG; Lanza C; Blandamura S; Marioni G
Oral Oncol; 2020 Sep; 108():104836. PubMed ID: 32512470
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
Franz L; Alessandrini L; Fasanaro E; Gaudioso P; Carli A; Nicolai P; Marioni G
Ann Diagn Pathol; 2021 Feb; 50():151657. PubMed ID: 33189034
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis, programmed death ligand 1 (PD-L1) and immune microenvironment association in laryngeal carcinoma.
Franz L; Alessandrini L; Calvanese L; Crosetta G; Frigo AC; Marioni G
Pathology; 2021 Dec; 53(7):844-851. PubMed ID: 33994172
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
[TBL] [Abstract][Full Text] [Related]
6. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of CD103
Smith JD; Bellile EL; Ellsperman SE; Heft-Neal ME; Mann JE; Birkeland AC; Hoesli RC; Swiecicki PL; Worden FP; Schonewolf C; Shah JL; Mierzwa ML; Rosko AJ; Stucken CL; Chinn SB; Shuman AG; Casper KA; Malloy KM; Prince MEP; Wolf GT; Thomas DG; McHugh JB; Chad Brenner J; Spector ME
Oral Oncol; 2022 Dec; 135():106226. PubMed ID: 36323071
[TBL] [Abstract][Full Text] [Related]
8. Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma.
Yang Z; Wang J; Chen C; Sun P; Yu Y
Technol Cancer Res Treat; 2021; 20():15330338211046432. PubMed ID: 34632870
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma.
Sato F; Ono T; Kawahara A; Matsuo K; Kondo R; Sato K; Akiba J; Kawaguchi T; Kakuma T; Chitose SI; Umeno H; Yano H
Laryngoscope; 2021 May; 131(5):E1481-E1488. PubMed ID: 33022760
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Amoils M; Kim J; Lee C; Sunwoo JB; Colevas AD; Aasi SZ; Hollmig ST; Ma Y; Divi V
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):93-99. PubMed ID: 30012051
[TBL] [Abstract][Full Text] [Related]
12. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
[TBL] [Abstract][Full Text] [Related]
15. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
[TBL] [Abstract][Full Text] [Related]
16. Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration.
Yu D; Cheng J; Xue K; Zhao X; Wen L; Xu C
Pathol Oncol Res; 2019 Oct; 25(4):1437-1443. PubMed ID: 30361911
[TBL] [Abstract][Full Text] [Related]
17. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.
Cocks M; Chaux A; Jenson EG; Miller JA; Rodriguez Pena MDC; Tregnago AC; Taheri D; Eich ML; Sharma R; Vang R; Netto GJ
Virchows Arch; 2020 Jul; 477(1):93-102. PubMed ID: 31993774
[TBL] [Abstract][Full Text] [Related]
19. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
Lien HC; Lee YH; Chen IC; Lin CH; Chen TW; Lu YT; Lu YS
Virchows Arch; 2021 Apr; 478(4):669-678. PubMed ID: 33089401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
